
Novo Nordisk shares plunge on the back of disappointing trial results
Published on December 25, 2024
latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on

latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on